HBOT Indicated UHMS Recognized

Sudden Sensorineural Hearing Loss Treatment with Hyperbaric Oxygen Therapy

Idiopathic sudden sensorineural hearing loss requires fast action. HBOT may improve outcomes by delivering oxygen to the delicate structures of the inner ear.

Understanding Sudden Sensorineural Hearing Loss

Idiopathic sudden sensorineural hearing loss (ISSHL) is an unexplained, rapid loss of hearing — usually in one ear — that occurs over the course of hours to a few days. It is defined as a loss of at least 30 decibels across three connected frequencies.

The inner ear (cochlea) is extremely sensitive to changes in blood flow and oxygen supply. While the exact cause of ISSHL is often unknown, it is believed to involve disruption of blood flow to the cochlea, viral inflammation, or autoimmune processes. Without prompt treatment, the hearing loss can become permanent.

ISSHL is a medical urgency. The window for effective treatment is narrow — most specialists recommend that treatment begin within two weeks of onset for the best chance of recovery.

How Hyperbaric Oxygen Therapy Helps

HBOT increases the oxygen available to the cochlear structures by dramatically raising the oxygen dissolved in blood plasma. Because the inner ear has a limited blood supply and no ability to store oxygen, it is particularly sensitive to oxygen deficiency — and particularly responsive to increased oxygen delivery.

The UHMS recognizes ISSHL as an indication for HBOT. Clinical evidence, including randomized controlled trials, suggests that HBOT used alongside standard steroid therapy may improve hearing recovery compared to steroids alone, particularly when initiated early after symptom onset.

What to Expect During Treatment

Treatment typically involves 10 to 20 sessions, each lasting approximately 90 minutes. Because timing is critical, treatment is ideally started as soon as possible after diagnosis — within the first 14 days. Your otolaryngologist (ENT specialist) coordinates with our hyperbaric team throughout the process.

Insurance & Coverage

This indication is recognized by the Undersea and Hyperbaric Medical Society (UHMS) and supported by peer-reviewed clinical evidence. It is not currently covered by Medicare under NCD 20.29. Coverage may be available through select commercial insurance plans. Our team will help verify your specific coverage and discuss all available options.

Our team handles the paperwork so you can focus on healing. We will verify your benefits, obtain any required prior authorizations, and keep you informed every step of the way.

Every Day Matters When a Wound Will Not Heal

The sooner you start treatment, the better your chances of a full recovery. Take the first step today.